TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9262882
Drug: 0.66 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.66 mg/kg PPA
Study: 9262882
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg PSE
Study: 9262882
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg PSE
Study: 8334179
Drug: 1.8 g
Normalized name: Calciquid, 1.8 g/5 mL oral syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 g protein/kg/day (high N diet)
Study: 8334179
Drug: 1.2 g
Normalized name: Humidifier 1.2 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 g protein/kg/day (low N diet)
Study: 23539236
Drug: Dexamethasone (14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (14 mg tapered over 3 days)
Study: 23539236
Drug: Intensive glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive glucose control (80-110 mg dl(‐1))
Study: 23539236
Drug: Conventional glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional glucose control (180-200 mg dl(‐1))
Study: 17904917
Drug: Patient preference
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient preference depression treatment
Study: 12960555
Drug: Inhaled morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled morphine (3 inhalations [6.6 mg])
Study: 12960555
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine (4 mg)
Study: 12960555
Drug: Inhaled morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled morphine (1 inhalation [2.2 mg])
Study: 10583449
Drug: Remikiren (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remikiren (600 mg day‐1) single dose
Study: 10583449
Drug: Remikiren (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remikiren (600 mg day‐1) multiple doses (8 days)
Study: 2021138
Drug: Increased dietary
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Increased dietary calcium (milk supplement, 831 mg/d)
Study: 2021138
Drug: Placebo drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drink (41 mg/d)
Study: 23016532
Drug: Skincare regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skincare regimen containing retinol, adenosine, and hyaluronic acid applied for 2 months after botulinum toxin A injection
Study: 19909752
Drug: Peginterferon alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peginterferon alfa-2a 180 microg/wk plus ribavirin 1000/1200 mg/day for 48 weeks (group A)
Study: 19909752
Drug: Peginterferon alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peginterferon alfa-2a 180 microg/wk plus ribavirin 1000/1200 mg/day for 72 weeks (group B)
Study: 12042561
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil 20 mg/kg/d
Study: 12042561
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil 30 mg/kg/d
Study: 12042561
Drug: Amoxicillin 50
Normalized name: amoxicillin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 50 mg/kg/d
Study: 1234631
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with melphalan
Study: 27277839
Drug: B-clade Tat
Approvals — FDA: no, EMA: no, PMDA: no
Description: B-clade Tat immunization (30 μg, intradermally, three times at 4-week intervals)
Study: 22872346
Drug: Educational actions
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational actions on oral health (school and home visits)
Study: 22872346
Drug: Educational actions
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational actions on oral health (school group)
Study: 20169425
Drug: Thalidomide, lenalidomide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide, lenalidomide, and bortezomib (new therapies)
Study: 18946688
Drug: ADCON-L (bioresorbable
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADCON-L (bioresorbable carbohydrate polymer gel)
Study: 18946688
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no ADCON-L)
Study: 18946688
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (ADCON-L and Control)
Study: 15567452
Drug: Unfractionated heparin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unfractionated heparin, 250 units/kg (n=15)
Study: 15567452
Drug: Enoxaparin, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin, 1 mg/kg (n=16)
Study: 9524046
Drug: Clonidine (transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (transdermal patch 2.5 mg/week)
Study: 6351669
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg glucose-free bupivacaine (0.5% or 0.75%)
Study: 6351669
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg glucose-free bupivacaine (0.5% or 0.75%)
Study: 6351669
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg glucose-free bupivacaine (0.5% or 0.75%)
Study: 6351669
Drug: Bupivacaine (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (various doses)
Study: 31815260
Drug: Low-dose L.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose L. casei (1 bottle per day, n = 142)
Study: 31815260
Drug: High-dose L.
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose L. casei (2 bottles per day, n = 143)
Study: 31815260
Drug: Low-dose L.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose L. casei
Study: 31815260
Drug: High-dose L.
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose L. casei
Study: 30825384
Drug: Systemic amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic amoxicillin 500 mg/metronidazole 400 mg (3×/day, 7 days, n = 170)
Study: 29476990
Drug: Oral TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral TXA (3 doses of 2 g oral TXA postoperatively)
Study: 29476990
Drug: Intravenous TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous TXA (3 doses of 1 g intravenous TXA postoperatively)
Study: 27139422
Drug: DHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA supplementation (1.16 g DHA/day for 8 weeks)
Study: 22094353
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (HT, n=34)
Study: 22094353
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy plus atorvastatin (HT+AT, n=36)
Study: 21290833
Drug: Medication (Diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (Diclofenac Sodium)
Study: 17704022
Drug: 100 mg/d
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/d gamma-tocopherol
Study: 17704022
Drug: 200 mg/d
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/d gamma-tocopherol
Study: 11837380
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg ASA (oral)
Study: 11837380
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg D,L‐lysine‐mono‐acetylsalicylate (Lys‐ASA) (oral and intravenous)
Study: 11837380
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg Lys‐ASA (oral)
Study: 9428456
Drug: Total-dose intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total-dose intravenous iron dextran infusion
Study: 9428456
Drug: 500-mg infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500-mg infusion to total dose
Study: 9428456
Drug: 100-mg bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100-mg bolus to total dose
Study: 2200632
Drug: Iopromide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iopromide (50 or 100 ml, 370 mgI/ml)
Study: 2200632
Drug: Iopamidol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iopamidol (50 or 100 ml, 370 mgI/ml)
Study: 7387335
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg beta-endorphin intravenous injection
Study: 7387335
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg morphine sulfate
Study: 27810904
Drug: Motolimod (VTX-2337)
Normalized name: Motolimod
DrugBank: Motolimod (DB12303)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motolimod (VTX-2337) at 3.0 mg/m2 combined with cetuximab
Study: 27810904
Drug: Motolimod (VTX-2337)
Normalized name: Motolimod
DrugBank: Motolimod (DB12303)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motolimod (VTX-2337) at 3.5 mg/m2 combined with cetuximab
Study: 14572304
Drug: Rescue medication
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue medication (oxygen, dexamethasone, acetazolamide)
Study: 11269488
Drug: Lung volume
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung volume reduction surgery (LVRS) plus medical therapy
Study: 2141488
Drug: Diethyl stilboestrol
Normalized name: Diethyl Phthalate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diethyl stilboestrol (DES) 3 mg/day
Study: 2141488
Drug: Goserelin 3.6
Normalized name: goserelin 3.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin 3.6 mg/month
Study: 271171
Drug: Vigorous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigorous treatment (CAT)
Study: 31492102
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard treatment based on Surviving Sepsis Campaign guidelines)
Study: 21324133
Drug: Directly Administered
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Directly Administered Antiretroviral Therapy (DAART) for 12 months
Study: 17061611
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (2000 mg per day for 20 days)
Study: 9713447
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide 1600 micrograms per day
Study: 2493897
Drug: Captopril (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (two 25 mg doses in 24 hours)
Study: 2493897
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two tablets in 24 hours)
Study: 31264510
Drug: PF-06412562 45
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06412562 45 mg
Study: 31264510
Drug: PF-06412562 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06412562 (3 mg, 9 mg, 45 mg)
Study: 28364099
Drug: Dexmedetomidine (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1.0 μg/kg loading dose for 10 min followed by 0.5 μg/(kg.h) during OLV)
Study: 25645599
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy (15 minutes daily)
Study: 21336094
Drug: E-MA-H low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: E-MA-H low dose (HLD)
Study: 21336094
Drug: E-MA-H high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: E-MA-H high dose (HHD)
Study: 11421839
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg hyperbaric bupivacaine injected through a 24G Sprotte needle, sitting for 1 min before supine position
Study: 11421839
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg hyperbaric bupivacaine injected through a 27G Whitacre needle, sitting for 1 min before supine position
Study: 11421839
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg hyperbaric bupivacaine injected through a 24G Sprotte needle, sitting for 4 min before supine position
Study: 11421839
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg hyperbaric bupivacaine injected through a 27G Whitacre needle, sitting for 4 min before supine position
Study: 2939715
Drug: Diclofenac (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (50 to 75 mg daily, or up to 150 mg per day for longer-term use)
Study: 8895942
Drug: Levomethadone maintenance
Normalized name: levomethadone
DrugBank: Levomethadone (DB13515)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levomethadone maintenance therapy
Study: 8895942
Drug: Drug-free placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-free placebo control group
Study: 27251956
Drug: Group L
Normalized name: Blood group Lewis alpha-4-fucosyltransferase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group L (levobupivacaine and fentanyl)
Study: 21342456
Drug: Lipid-based nutrient
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based nutrient supplement (50 g, 264 kcal)
Study: 21342456
Drug: Lipid-based nutrient
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based nutrient supplement (25 g, 130 kcal)
Study: 21342456
Drug: Corn-soy flour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn-soy flour (71 g, 282 kcal)
Study: 8695926
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy protocol of six days
Study: 8695926
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy protocol of one day
Study: 6196073
Drug: Bendrofluazide (thiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendrofluazide (thiazide treatment)
Study: 6196073
Drug: Bendrofluazide (long
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendrofluazide (long term treatment)
Study: 6196073
Drug: Bendrofluazide with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendrofluazide with potassium supplements (long term treatment)
Study: 6196073
Drug: Placebo (long
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (long term treatment)
Study: 21403978
Drug: H. persicum
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. persicum extract (500 mg/day) + atorvastatin (10 mg/day) for 8 weeks
Study: 21403978
Drug: Atorvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (20 mg/day) for 8 weeks
Study: 19564812
Drug: Inactivated virosomal‐adjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated virosomal‐adjuvanted subunit influenza vaccine (n = 90)
Study: 19564812
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (n = 90)
Study: 11507355
Drug: amoxycillin 1
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: amoxycillin 1 g bid, metronidazole 500 mg bid, bismuth sub‐citrate 240 mg bid and ranitidine 300 mg bid for 1 week
Study: 11507355
Drug: triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: triple therapy without ranitidine for 2 weeks
Study: 11507355
Drug: triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: triple therapy plus ranitidine 300 mg bid for 2 weeks
Study: 9513613
Drug: Oral 17
Normalized name: polyoxypropylene (17)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 17 beta estradiol 2 mg per day
Study: 9513613
Drug: Transdermal 17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17 beta estradiol 50 micrograms per day
Study: 8678131
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens 0.625 mg per day
Study: 9513613
Drug: 17 beta
Normalized name: 17 beta-estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 beta estradiol gel 1.5 micrograms per day
Study: 9513613
Drug: Delayed estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed estrogen replacement therapy (at 65 years of age)
Study: 8498533
Drug: Bromocriptine (BRC)
DrugBank: Bromocriptine (DB01200)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bromocriptine (BRC) 1.25 mg per os
Study: 3591727
Drug: Aquabiosorb soft
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aquabiosorb soft elastic gelatin (SEG) capsule
Study: 3591727
Drug: modified standard‐SEG
Approvals — FDA: no, EMA: no, PMDA: no
Description: modified standard‐SEG capsule
Study: 3591727
Drug: commercial tablet
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: commercial tablet
Study: 3591727
Drug: SEG formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: SEG formulation
Study: 28272972
Drug: Solution‐Focused Coaching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution‐Focused Coaching in pediatric rehabilitation (SFC‐Peds)
Study: 26638119
Drug: Memantine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine (10 mg/day)
Study: 22219334
Drug: Intravenous colloid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous colloid volume loading (11 ml kg⁻¹) during heat stress
Study: 20303444
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of DTaP‐HBV‐IPV/Hib at 12 to 23 months
Study: 17012885
Drug: Active specific
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active specific immunotherapy with autologous tumor cell vaccines
Study: 14614670
Drug: Intravenous azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous azithromycin (500 mg/day) for 2-7 days, followed by oral azithromycin (1500 mg over 3 or 5 days)
Study: 10908823
Drug: Controlled-release metoclopramide
Normalized name: metoclopramide Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release metoclopramide 40 mg every 12 hours
Study: 8694208
Drug: 1% propofol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% propofol infusion at 0.1 ml.kg‐1.h‐1 for 24 h after surgery
Study: 8694208
Drug: Intralipid infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid infusion at 0.1 ml.kg‐1.h‐1 for 24 h after surgery (Control)
Study: 4070323
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg pivmecillinam plus 250 mg pivampicillin given twice daily
Study: 4070323
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg amoxycillin given 3-times daily
Study: 31906751
Drug: Dexmedetomidine 1 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 1 μg/kg + 0.25 mcg/kg/h (group D1)
Study: 31906751
Drug: Dexmedetomidine 1 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 1 μg/kg + 0.5 mcg/kg/h (group D2)
Study: 31906751
Drug: Dexmedetomidine 1 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 1 μg/kg + 1 mcg/kg/h (group D3)
Study: 30485853
Drug: Intensive statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive statin (atorvastatin 60 mg/day, adjusted to 20 mg/day after 7 days)
Study: 30485853
Drug: Control (atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (atorvastatin 20 mg/day)
Study: 28302075
Drug: Zinc (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc (60 mg) administration
Study: 16176203
Drug: Hyperglycaemia (blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperglycaemia (blood glucose level at 16 mmol/l for 3 hours)
Study: 16176203
Drug: Normoglycaemia (blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normoglycaemia (blood glucose level at 5 mmol/l for 3 hours)
Study: 12591750
Drug: ivabradine 5
Normalized name: ivabradine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ivabradine 5 mg BID
Study: 12591750
Drug: ivabradine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ivabradine 10 mg BID
Study: 8678158
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 gel (4 mg, 2 applications 4 hours apart)
Study: 6352601
Drug: Azlocillin at
Normalized name: azlocillin
DrugBank: Azlocillin (DB01061)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Azlocillin at 8 g/day
Study: 6352601
Drug: Ticarcillin at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticarcillin at 12 g/day
Study: 24703486
Drug: Physiologic replacement-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiologic replacement-dose recombinant human leptin (metreleptin)
Study: 24703486
Drug: Leptin treatment
Normalized name: leptin
DrugBank: Leptin (DB05098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leptin treatment in vitro
Study: 11368138
Drug: Uterine artery
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uterine artery Doppler screening followed by 100 mg of aspirin daily until the 35th week
Study: 11368138
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no Doppler screening and no aspirin treatment)
Study: 8508709
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (tetracycline hydrochloride 500 mg four times a day for days 0-14 and metronidazole 500 mg three times a day for days 15-28)
Study: 8508709
Drug: Colloidal bismuth
Normalized name: Colloidal bismuth subcitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloidal bismuth subcitrate (120 mg four times a day for 8 weeks)
Study: 8508709
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy offered to six patients on bismuth whose ulcers remained unhealed or relapsed early after healing
Study: 3729081
Drug: Transdermal azatadine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal azatadine maleate TDDS
Study: 3729081
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral doses of azatadine
Study: 29783269
Drug: Intravenous ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous ibuprofen + paracetamol (n = 12)